PT3679034T - Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica - Google Patents
Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónicaInfo
- Publication number
- PT3679034T PT3679034T PT187621115T PT18762111T PT3679034T PT 3679034 T PT3679034 T PT 3679034T PT 187621115 T PT187621115 T PT 187621115T PT 18762111 T PT18762111 T PT 18762111T PT 3679034 T PT3679034 T PT 3679034T
- Authority
- PT
- Portugal
- Prior art keywords
- methylpropan
- isoxazol
- pyrazol
- ifn
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189652 | 2017-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3679034T true PT3679034T (pt) | 2022-08-29 |
Family
ID=59799324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT187621115T PT3679034T (pt) | 2017-09-06 | 2018-09-06 | Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11292788B2 (pt) |
| EP (2) | EP3679034B1 (pt) |
| JP (2) | JP2020532575A (pt) |
| KR (1) | KR20200069299A (pt) |
| CN (1) | CN111433202A (pt) |
| AU (1) | AU2018330633C1 (pt) |
| CA (1) | CA3074891A1 (pt) |
| DK (1) | DK3679034T3 (pt) |
| ES (1) | ES2925538T3 (pt) |
| HR (1) | HRP20221042T1 (pt) |
| HU (1) | HUE059822T2 (pt) |
| IL (1) | IL273064B2 (pt) |
| LT (1) | LT3679034T (pt) |
| MA (1) | MA50069B1 (pt) |
| MD (1) | MD3679034T2 (pt) |
| MX (1) | MX2020002571A (pt) |
| PH (1) | PH12020500461A1 (pt) |
| PL (1) | PL3679034T3 (pt) |
| PT (1) | PT3679034T (pt) |
| RS (1) | RS63532B1 (pt) |
| SG (1) | SG11202001409UA (pt) |
| SI (1) | SI3679034T1 (pt) |
| UA (1) | UA126689C2 (pt) |
| WO (1) | WO2019048541A1 (pt) |
| ZA (1) | ZA202001179B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023281097A1 (en) | 2021-07-09 | 2023-01-12 | Immunic Ag | Methods for treating cancer |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| WO2023198873A1 (en) | 2022-04-14 | 2023-10-19 | Immunic Ag | Deuterated rorgamma/rorgammat inverse agonists |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668182B1 (en) * | 2011-01-28 | 2017-11-01 | 4SC Discovery GmbH | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation |
| MX348726B (es) * | 2011-01-28 | 2017-06-26 | 4Sc Discovery Gmbh | Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune. |
-
2018
- 2018-09-06 CN CN201880058056.9A patent/CN111433202A/zh active Pending
- 2018-09-06 WO PCT/EP2018/073993 patent/WO2019048541A1/en unknown
- 2018-09-06 SG SG11202001409UA patent/SG11202001409UA/en unknown
- 2018-09-06 US US16/644,581 patent/US11292788B2/en active Active
- 2018-09-06 MX MX2020002571A patent/MX2020002571A/es unknown
- 2018-09-06 PT PT187621115T patent/PT3679034T/pt unknown
- 2018-09-06 SI SI201830741T patent/SI3679034T1/sl unknown
- 2018-09-06 CA CA3074891A patent/CA3074891A1/en active Pending
- 2018-09-06 MA MA50069A patent/MA50069B1/fr unknown
- 2018-09-06 KR KR1020207009871A patent/KR20200069299A/ko not_active Application Discontinuation
- 2018-09-06 AU AU2018330633A patent/AU2018330633C1/en active Active
- 2018-09-06 HR HRP20221042TT patent/HRP20221042T1/hr unknown
- 2018-09-06 UA UAA202002206A patent/UA126689C2/uk unknown
- 2018-09-06 PL PL18762111.5T patent/PL3679034T3/pl unknown
- 2018-09-06 JP JP2020514532A patent/JP2020532575A/ja active Pending
- 2018-09-06 EP EP18762111.5A patent/EP3679034B1/en active Active
- 2018-09-06 HU HUE18762111A patent/HUE059822T2/hu unknown
- 2018-09-06 EP EP22176185.1A patent/EP4074708A1/en not_active Withdrawn
- 2018-09-06 ES ES18762111T patent/ES2925538T3/es active Active
- 2018-09-06 LT LTEPPCT/EP2018/073993T patent/LT3679034T/lt unknown
- 2018-09-06 MD MDE20200707T patent/MD3679034T2/ro unknown
- 2018-09-06 RS RS20220796A patent/RS63532B1/sr unknown
- 2018-09-06 DK DK18762111.5T patent/DK3679034T3/da active
-
2020
- 2020-02-25 ZA ZA2020/01179A patent/ZA202001179B/en unknown
- 2020-03-04 IL IL273064A patent/IL273064B2/en unknown
- 2020-03-06 PH PH12020500461A patent/PH12020500461A1/en unknown
-
2022
- 2022-12-23 JP JP2022206807A patent/JP2023052060A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273064A (en) | 1-(4-(Isoxazol-5-yl)-H1-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as IL-17 and IFN-gamma suppressors for the treatment of autoimmune diseases and chronic inflammation | |
| HUE061599T2 (hu) | KRas G12C inhibotorok | |
| EP3307728A4 (en) | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | |
| IL254736B (en) | Imidazole [1,2-c]pyrimidine derivative compounds, 1LSD inhibitors, pharmaceutical compound comprising them and use for cancer treatment | |
| EP3247353A4 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| IL275948A (en) | History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses | |
| SI3700902T1 (sl) | Inhibitorji trpc6 | |
| EP3310776A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| IL273585A (en) | Therapeutic methods related to HSP90 inhibitors | |
| EP3638229A4 (en) | IMIDAZOLE INHIBITORS FROM ALK2-KINASE | |
| IL281371A (en) | Indazole carboxamides as kinase inhibitors | |
| IL279453B (en) | Pyrazole history as malt1 inhibitors | |
| EP3609882A4 (en) | HETEROCYCLIC INHIBITORS OF PCSK9 | |
| IL258870A (en) | Substituted indazole compounds as rorgammat inhibitors and uses thereof | |
| IL279452B (en) | Pyrazole history as malt1 inhibitors | |
| IL279348A (en) | Pyrazole and imidazole compounds as IL-17 and ROR gamma tracers | |
| EA031679B9 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| EP3749647C0 (en) | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | |
| HK1248119A1 (zh) | 有機氧化砷化合物和mtor抑制劑的藥物組合 | |
| EP3568128A4 (en) | HSP90B-N-TERMINALS ISOFORM SELECTIVE INHIBITORS | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| PL3364971T3 (pl) | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu | |
| EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY |